|
Aug 1
|
Regeneron cancer bispecific rejected again; Allogene discloses trial death
|
|
Aug 1
|
Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics
|
|
Aug 1
|
Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus
|
|
Jul 31
|
Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate
|
|
Jul 31
|
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
|
|
Jul 31
|
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Jul 31
|
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
|
|
Jul 31
|
Biogen (NASDAQ:BIIB) Reports Bullish Q2
|
|
Jul 31
|
Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates
|
|
Jul 31
|
Biogen lifts full-year outlook amid Alzheimer’s drug strength, sending shares up
|
|
Jul 31
|
Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
|
|
Jul 31
|
Biogen raises annual profit forecast on strong demand for rare disease drugs
|
|
Jul 31
|
Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA
|
|
Jul 30
|
Sage Therapeutics Announces Second Quarter 2025 Financial Results
|
|
Jul 30
|
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
|
|
Jul 30
|
Biogen (BIIB) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
|
|
Jul 30
|
New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
|
|
Jul 30
|
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
|
|
Jul 30
|
Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLL
|
|
Jul 30
|
Biogen Earnings: What To Look For From BIIB
|